57734-73-3

Usage

Molecular structure

2-(1-azabicyclo[2.2.2]oct-3-yl)-1,1-diphenylethanol is a synthetic chemical compound with a specific molecular structure that includes a tropane alkaloid class.

Pharmacological effects

Tropacocaine acts as a stimulant and local anesthetic, similar to cocaine.

Neurotransmitter inhibition

Tropacocaine is a potent inhibitor of dopamine and norepinephrine reuptake, making it a potential candidate for the treatment of ADHD and other related disorders.

Legal status

Due to its high abuse potential and potential for addiction, tropacocaine is classified as a controlled substance in many countries and is not approved for medical or recreational use.

Upstream product

• 57734-93-7 ethyl 1-azabicyclo<2.2.2>oct-3-ylacetate 
• 100-58-3 phenylmagnesium bromide 
• 54238-09-4 3-(1-azabicyclo[2.2.2]oct-3-ylidene)-3-acetic acid ethyl ester 
• 3731-38-2 3-Quinuclidinone 

Relevant academic research and scientific papers

QUINUCLIDINE DERIVATIVE

Provided is a novel therapeutic agent for chronic obstructive pulmonary disease. Provided are a quinuclidine derivative and a medicament comprising the quinuclidine derivative. wherein R1 represents a hydrogen atom, a halogen atom, a lower alkyl group, a haloalkyl group, a lower alkoxy group, or a haloalkoxy group; Y represents —C(C═O)—O—, —CH2—, or —CH2O—; m represents an integer of 1 to 5; Z represents an oxygen atom or a sulfur atom; l represents a number of 0 or 1; n represents an integer of 0 to 4; X? represents an anion; and a substituent of a quinuclidine ring represents a 1,3-bond, or 1,4-bond, provided that when m is 3, l is 1, and n is 0, R1 represents a halogen atom, a lower alkyl group, a haloalkyl group, a lower alkoxy group, or a haloalkoxy group.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists

A novel 4-hydroxyl(diphenyl)methyl substituted quinuclidine series was discovered as a very promising class of muscarinic antagonists. The structure-activity relationships of the connectivity of the diphenyl moiety to the quinuclidine core and around the ring nitrogen side chain are described. Computational docking studies using an homology model of the M3 receptor readily explained the observed structure-activity relationship of the various compounds. Compound 14o was identified as a very potent, slowly reversible M3 antagonist with a very long in vivo duration of bronchoprotection.